Bajaj Healthcare (BAJAJHCARE)₹315.25+0.02%Pharmaceuticals
In the Jun 2026 quarter (standalone), Bajaj Healthcare reported sales of ₹165 Cr, up 11.5% from Jun 2025, and net profit of ₹13.99 Cr, up 16.5% year on year. For the year to Mar 2026, sales were ₹608 Cr and net profit ₹15.99 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 101 | 109 | 133 | 132 | 133 | 123 | 153 | 148 | 148 | 160 | 152 | 165 |
| Expenses | 82.03 | 89.12 | 118 | 108 | 109 | 101 | 143 | 124 | 121 | 131 | 130 | 137 |
| Operating Profit | 18.97 | 19.97 | 15.98 | 23.95 | 24.95 | 21.98 | 11.98 | 24.94 | 26.94 | 30.93 | 22.96 | 28.96 |
| OPM % | 19.0% | 18.0% | 12.0% | 19.0% | 18.0% | 18.0% | 8.0% | 16.0% | 18.0% | 19.0% | 15.0% | 17.0% |
| Other Income | −6.98 | −6.98 | −35.86 | 0.00 | 3.99 | −0.99 | 12.94 | 0.99 | 0.00 | 0.99 | −33.90 | 0.99 |
| Interest | 8.02 | 7.01 | 6.01 | 8.01 | 8.01 | 6.02 | 6.02 | 5.01 | 6.02 | 6.01 | 6.01 | 6.02 |
| Depreciation | 7.02 | 7.02 | 7.02 | 7.02 | 7.02 | 7.01 | 8.02 | 6.01 | 7.02 | 7.02 | 8.03 | 7.02 |
| Profit before tax | −3.01 | −1.01 | −33.11 | 9.03 | 14.06 | 8.03 | 11.04 | 14.05 | 15.04 | 19.06 | −24.07 | 16.07 |
| Tax % | 4.0% | 58.0% | −10.0% | 23.0% | 30.0% | −39.0% | 1.0% | 17.0% | 24.0% | 17.0% | −6.0% | 16.0% |
| Exceptional items | −8.59 | −7.73 | −42.28 | −0.90 | 1.13 | −3.25 | −0.43 | −0.35 | −1.35 | −0.44 | −36.70 | −0.20 |
| Net Profit | −2.99 | −1.99 | −29.98 | 7.01 | 9.01 | 12.01 | 11.01 | 12.01 | 10.99 | 16.01 | −22.99 | 13.99 |
| EPS (Rs) | −1.26 | −0.81 | −10.88 | 2.59 | 3.01 | 3.72 | 3.55 | 3.76 | 3.53 | 4.98 | −6.82 | 4.09 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 222 | 230 | 326 | 369 | 409 | 655 | 678 | 644 | 471 | 541 | 608 | 626 |
| Expenses | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 535 | 397 | 460 | 506 | 519 |
| Operating Profit | 29.93 | 30.92 | 38.95 | 42.90 | 47.90 | 136 | 119 | 112 | 75.92 | 82.89 | 105 | 110 |
| OPM % | 14.0% | 13.0% | 12.0% | 12.0% | 12.0% | 21.0% | 17.0% | 17.0% | 16.0% | 15.0% | 17.0% | 17.6% |
| Other Income | 0.00 | 1.99 | 1.99 | 0.99 | 6.97 | 6.97 | 0.99 | −18.94 | −105 | 15.93 | −31.90 | −31.92 |
| Interest | 8.02 | 8.02 | 8.02 | 8.02 | 7.01 | 8.02 | 13.03 | 18.04 | 30.05 | 28.08 | 22.05 | 24.06 |
| Depreciation | 9.03 | 11.04 | 11.03 | 11.04 | 12.04 | 16.04 | 18.06 | 17.05 | 28.07 | 28.08 | 28.09 | 29.09 |
| Profit before tax | 14.04 | 14.05 | 23.07 | 24.06 | 36.13 | 119 | 90.28 | 58.18 | −86.28 | 43.17 | 23.07 | 26.10 |
| Tax % | 39.0% | 43.0% | 33.0% | 33.0% | 30.0% | 30.0% | 20.0% | 25.0% | −3.0% | 7.0% | 33.0% | — |
| Exceptional items | −0.06 | −0.04 | 0.00 | −0.12 | 0.03 | 0.02 | 0.00 | 0.00 | −44.32 | −0.32 | −31.20 | −38.69 |
| Net Profit | 7.99 | 7.99 | 14.99 | 16.01 | 24.99 | 83.03 | 70.96 | 43.01 | −83.95 | 40.01 | 15.99 | 18.00 |
| EPS (Rs) | 3.05 | 2.84 | 5.52 | 5.93 | 9.17 | 30.19 | 25.97 | 15.66 | −30.46 | 12.55 | 4.70 | 5.78 |
| Dividend payout % | 0.0% | 0.0% | 5.0% | 0.0% | 0.0% | 5.0% | 6.0% | 6.0% | −3.0% | 8.0% | 31.9% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.99 | 7.01 | 7.00 | 7.01 | 7.01 | 14.01 | 14.00 | 14.02 | 13.98 | 13.99 | 15.99 | 17.00 |
| Reserves | 78.06 | 82.05 | 92.01 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 450 | 516 |
| Borrowings | 70.24 | 81.25 | 75.19 | 87.29 | 81.27 | 91.28 | 181 | 258 | 416 | 334 | 223 | 249 |
| Other Liabilities | 37.93 | 38.81 | 44.78 | 67.81 | 56.72 | 73.65 | 85.58 | 135 | 114 | 153 | 143 | 140 |
| Total Liabilities | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 832 | 923 |
| Fixed Assets | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 271 | 366 | 253 | 238 | 248 |
| CWIP | 1.01 | 1.01 | 0.00 | 2.01 | 1.01 | 4.99 | 56.99 | 52.01 | 22.01 | 6.99 | 2.99 | 8.01 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 78.96 | 77.96 | 90.88 | 140 | 137 | 170 | 260 | 399 | 509 | 506 | 590 | 667 |
| Inventories | 18.01 | 20.01 | 17.01 | 34.03 | 30.03 | 39.03 | 97.07 | 159 | 209 | 144 | 162 | 216 |
| Trade receivables | 52.06 | 43.03 | 53.07 | 80.10 | 78.01 | 98.11 | 99.04 | 185 | 194 | 180 | 252 | 234 |
| Cash & equivalents | 0.99 | 0.00 | 0.99 | 7.98 | 7.98 | 3.99 | 13.98 | 1.99 | 18.95 | 2.99 | 3.99 | 37.91 |
| Total Assets | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 832 | 923 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 27.99 | 24.99 | 22.01 | 16.99 | 24.97 | 20.98 | 44.01 | 0.99 | −22.01 | 92.03 | 22.01 | 57.94 |
| Cash from investing activity | −17.01 | −31.01 | −8.01 | −11.99 | −12.99 | −28.01 | −109 | −74.98 | −92.97 | −11.01 | −15.01 | −48.01 |
| Cash from financing activity | −11.04 | 5.02 | −13.05 | 2.01 | −13.05 | 3.01 | 75.33 | 62.29 | 132 | −97.35 | −6.02 | 24.09 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 6.99 | 0.00 | −3.99 | 9.98 | −11.98 | 15.98 | −15.99 | 0.00 | 34.97 |
| Capex | 18.45 | 30.70 | 10.13 | 9.76 | 15.02 | 18.43 | 62.25 | 79.34 | 93.61 | 30.32 | 11.55 | 43.37 |
| Free cash flow | 10.98 | −5.98 | 13.97 | 4.99 | 10.97 | −1.99 | −69.84 | −73.87 | −115 | 72.80 | 9.98 | 17.95 |
| CFO / OP % | 99.0% | 100.0% | 88.0% | 57.0% | 89.0% | 62.0% | 58.0% | 9.0% | −10.0% | 138.0% | 32.0% | 53.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 85 | 69 | 82 | 89 | 76 | 87 | 54 | 98 | 109 | 138 | 168 | 139 |
| Inventory days | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 | 206 | 249 |
| Days payable | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 | 122 | 133 |
| Cash conversion cycle | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 | 254 | 256 |
| Working capital days | −11 | −17 | −4 | 0 | 12 | 24 | 34 | 40 | 27 | 0 | 140 | 119 |
| ROCE % | 15.9% | 12.9% | 13.0% | 15.9% | 16.0% | 17.9% | 35.9% | 19.9% | 13.9% | 7.9% | 10.9% | 10.9% |
For the Jun 2026 quarter, Bajaj Healthcare reported sales of ₹165 Cr, up 11.5% year on year and net profit of ₹13.99 Cr, up 16.5% year on year. The operating margin was 17.0%.
Bajaj Healthcare's sales for the year to Mar 2026 were ₹608 Cr; over the last twelve months they were ₹626 Cr.
Net profit for the year to Mar 2026 was ₹15.99 Cr, and ₹18 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.78.
Bajaj Healthcare reported borrowings of ₹249 Cr at Mar 2026, against cash and equivalents of ₹37.91 Cr.
Cash from operations was ₹57.94 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹17.95 Cr.